These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 28428285

  • 1. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T, Baohua Y, Xiaoli X, Yufan C, Xiaoyu T, Hongfen L, Rui B, Xiangjie S, Ruohong S, Wentao Y.
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Correlation between androgen receptor expression and surrogate molecular subtypes in invasive breast carcinoma].
    Sun XJ, Zuo K, Tang SX, Lu HF, Shui RH, Yu BH, Xu XL, Cheng YF, Tu XY, Bi R, Yang WT.
    Zhonghua Bing Li Xue Za Zhi; 2017 Jul 08; 46(7):476-480. PubMed ID: 28728221
    [Abstract] [Full Text] [Related]

  • 4. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
    Deftereos G, Sanguino Ramirez AM, Silverman JF, Krishnamurti U.
    Am J Surg Pathol; 2015 Sep 08; 39(9):1282-9. PubMed ID: 26274030
    [Abstract] [Full Text] [Related]

  • 5. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y, Lu S, Zeng W, Xie S, Xiao S.
    Ann Diagn Pathol; 2017 Feb 08; 26():1-5. PubMed ID: 28038704
    [Abstract] [Full Text] [Related]

  • 6. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW, Papadimos DJ, Walsh MD.
    Cancer Cytopathol; 2014 Apr 08; 122(4):307-12. PubMed ID: 24421220
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
    Krings G, Nystrom M, Mehdi I, Vohra P, Chen YY.
    Hum Pathol; 2014 Nov 08; 45(11):2225-32. PubMed ID: 25150746
    [Abstract] [Full Text] [Related]

  • 8. Differences in GATA3 expression among histological/molecular subtypes and grades in infiltrating breast carcinoma (IBC) are important in the diagnosis of metastatic breast carcinoma.
    Stolnicu S, Tunde C, Cadar A, Boros M.
    Pol J Pathol; 2020 Nov 08; 71(1):62-65. PubMed ID: 32429656
    [Abstract] [Full Text] [Related]

  • 9. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
    Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C, Li XB.
    Hum Pathol; 2016 Jan 08; 47(1):26-31. PubMed ID: 26527523
    [Abstract] [Full Text] [Related]

  • 10. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB, Tsang JYS, Shao MM, Chan SK, Cheung SY, Tong J, To KF, Tse GM.
    Breast Cancer Res Treat; 2018 May 08; 169(1):25-32. PubMed ID: 29340880
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH, Shaaban HM.
    Turk Patoloji Derg; 2018 May 08; 34(2):143-149. PubMed ID: 29235613
    [Abstract] [Full Text] [Related]

  • 13. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W, Guner G, Miyamoto H, Cimino-Mathews A, Gonzalez-Roibon N, Argani P, Li X, Sharma R, Subhawong AP, Rezaei K, Bivalacqua TJ, Epstein JI, Bishop JA, Netto GJ.
    Hum Pathol; 2015 Jan 08; 46(1):58-64. PubMed ID: 25449628
    [Abstract] [Full Text] [Related]

  • 14. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M, Pang JC, Jing X, Fields KL, Roh MH.
    Cancer Cytopathol; 2015 Oct 08; 123(10):576-81. PubMed ID: 26465236
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Male breast carcinoma: a clinicopathological and immunohistochemical characterization study.
    Zhou R, Yu L, Zhou S, Bi R, Shui R, Yu B, Lu H, Cai X, Yang W.
    Int J Clin Exp Pathol; 2014 Oct 08; 7(10):6852-61. PubMed ID: 25400768
    [Abstract] [Full Text] [Related]

  • 18. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM, Mentrikoski MJ, Wick MR.
    Ann Diagn Pathol; 2015 Feb 08; 19(1):6-9. PubMed ID: 25544392
    [Abstract] [Full Text] [Related]

  • 19. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases.
    Boto A, Harigopal M.
    Hum Pathol; 2018 May 08; 75():63-70. PubMed ID: 29408697
    [Abstract] [Full Text] [Related]

  • 20. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
    Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q.
    Mod Pathol; 2021 Apr 08; 34(4):710-719. PubMed ID: 33011748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.